Dr. Stinchcomb is involved in numerous research projects focused on the transdermal delivery of drugs to treat a wide range of diseases. Ongoing projects are listed below.
Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthritis
|R03DA030570 (Stinchcomb PI)||7/1/11-6/30/14||NIH/NIDA|
The major goal of this project is to optimize topical delivery of endocannabinoid-like structures.
Quantitative Detection of Cold Flow in Transdermal Systems
|U01FD005275 (Hoag and Stinchcomb, Co-PI)||3/1/12-9/1/13||NIPTE-FDA|
The goal of this project is to predict cold flow in transdermal systems using NIR spectroscopy.
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppression
|21DA31439 (Stinchcomb PI)||07/15/12-04/30/14||NIH/NIDA|
The goal of this project is to develop transdermal codrugs of hydroxybupropion and naltrexone.
Transdermal Naltrexone for Opiate Addiction and Alcoholism
|R42DA32191 (Stinchcomb PI)||08/01/12-07/30/14||NIH/NIDA|
The goal of this project is to develop a microneedle enhanced naltrexone transdermal delivery system.